Contraceptive care for adolescents

Clinical Obstetrics and Gynecology

Volumn 51, Issue 2, 2008, Pages 268-280

  Whitaker, Amy K ^a   Gilliam, Melissa ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Adolescents; Contraception; Pregnancy; Teenagers

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NON PRESCRIPTION DRUG; ORAL CONTRACEPTIVE AGENT; SPERMICIDAL AGENT;

ABSENCE OF SIDE EFFECTS; ADOLESCENCE; ADOLESCENT PREGNANCY; AMENORRHEA; ARM; BIRTH CONTROL; BLEEDING DISORDER; BODY WEIGHT; BONE DENSITY; BREAST TENDERNESS; CAUCASIAN; CLINICAL TRIAL; CONDOM; CONTRACEPTION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG IMPLANT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EMERGENCY CONTRACEPTION; FAMILY PLANNING; FEMALE INFERTILITY; GIRL; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAUTERINE CONTRACEPTIVE DEVICE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MOOD CHANGE; NAUSEA; NEGRO; ORAL CONTRACEPTION; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PELVIC INFLAMMATORY DISEASE; PREGNANCY RATE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN IRRITATION; TREATMENT FAILURE; TREATMENT WITHDRAWAL; UTERINE CERVICITIS; VAGINA BLEEDING; VAGINAL DISCOMFORT; WORLD HEALTH ORGANIZATION;

ADOLESCENT; CONDOMS; CONTRACEPTION; CONTRACEPTIVE DEVICES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; PREGNANCY; PREGNANCY IN ADOLESCENCE; PREGNANCY, UNWANTED; RISK FACTORS;

EID: 43249095783     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31816d713e     Document Type: Review

References (43)

1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90-96.
2. Ventura SJ, Abma JC, Mosher WD, et al. Recent trends in teenage pregnancy in the United States, 1990-2002. Health E-stats. Hyattsville, MD:NationalCenter for Health Statistics. Released December 13, 2006.
3. Abma JC, Martinez GM, Mosher WD, et al. Teenagers in the United States: Sexual activity, contraceptive use, and child-bearing, 2002. Vital Health Stat. 2004;23.
4. Santelli JS, Lindberg LD, Finer LB, et al. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. Am J Public Health. 2007;97:150-156.
5. Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data Vital Health Stat. 2004;350:1-36.
6. Hatcher RA, Trussel J, Stewart F, et al. Contraceptive Technology, 18th edn|. New York: Ardent Media; 2004.
7. Guttmacher Institute. Minors' Access to Contraceptive Services. State Policies in Brief, August 1, 2007. Available at: http://www.guttmacher.org/ statecenter/spibs/spib_MACS.pdf. Accessed August 19, 2007.
8. Jones RK, Purcell A, Singh S, et al. Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception. JAMA. 2005;293:340-348.
9. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 3rd edn. Geneva: World Health Organization; 2004.
10. Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J Pediatr Adolesc Gynecol. 2001;14:153-162.
11. Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: a review. Contraception. 1995;52:137-141.
12. Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol. 1999;12:90-94.
13. Gilliam M, Holmquist S, Berlin A. Factors associated with willingness to use the contraceptive vaginal ring. Contraception. 2007;76:30-34.
14. Carey AS, Chiappetta L, Tremont K, et al. The contraceptive vaginal ring: female adolescents' knowledge, attitudes and plans for use. Contraception. 2007;76:444-450.
15. Mishell D. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med. 1999;41(suppl):381-390.
16. Clark MK, Sowers M, Levy BT, et al. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril. 2001;75:871-877.
17. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG. 2001;108:1214-1221.
18. Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable Hormone Contraception and Bone Density: Results from a Prospective Study. Epidemiology. 2002;13:581-587.
19. Clark MK, Sowers M, Levy B, et al. Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2006;86:1466-1474.
20. Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception. 2006;74:90-99.
21. Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child. 2005;90:373-378.
22. Lloyd T, Rollings N, Andon MB, et al. Determinants of bone density in young women. J Clin Endocrinol Metab. 1992;75:383-387.
23. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bonemineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434-441.
24. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139-144.
25. Sowers MF, Scholl T, Harris L, et al. Bone loss in adolescent and adult pregnant women. Obstet Gynecol. 2000;96:189-193.
26. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents - The Black Box warning: a position paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296-301.
27. Implanont [package insert]. Roseland, NJ: Organon USA Inc; 2006.
28. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanons. Human Reproduction. 1999;14:976-981.
29. Funk S, Miller MM, Mishell DR, et al. Safety and efficacy of Implanons, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71:319-326.
30. Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during longterm use of the progestagen contraceptive implant Implanons compared to a nonhormonal method of contraception. Hum Reprod. 2000;15:118-122.
31. Daling JR, Weiss NS, Metch BJ, et al. Primary tubal infertility in relation to the use of an intrauterine device. N Engl J Med. 1985;312:937-941.
32. Cramer DW, Schiff I, Schoenbaum SC, et al. Tubal infertility and the intrauterine device. N Engl J Med. 1985;312:941-947.
33. Kronmal RA, Whitney CW, Mumford SD. The intrauterine device and pelvic inflammatory disease: the women's health study reanalyzed. J Clin Epidemiol. 1991;44:109-122.
34. Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339:785-788.
35. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during 5 years of use: a randomized comparative trial. Contraception. 1994;49:56-72.
36. Hubacher D, Lara-Ricalde R, Taylor D, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561-567.
37. Sivin I, Stern J. Long-acting, more effective copper T IUDs: a summary of U.S. experience, 1970-75. Stud Fam Plann. 1979;10:263-281.
38. Veldhuis HM, Vos AG, Lagro-Hanssen AL. Complications of the intrauterine device in nulliparous and parous women. Eur J Gen Pract. 2004;10:82-87.
39. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007;75:S8-S11.
40. Trussel J, Raymond E. Emergency Contraception: A last chance to prevent unintended pregnancy. Available at http://ec.princeton.edu/questions/ec-review. pdf.
41. Memo from Dr Andrew von Eschenbach, Acting FDA Commissioner, 8/24/2006. Available at: http://www.fda.gov/cder/drug/infopage/planB/default.htm. Accessed September 2, 2007.
42. Harper CC, Cheong M, Rocca CH, et al. The effect of increased access to emergency contraception among young adolescents. Obstet Gynecol. 2005;106:483-491.
43. Raymond EG, Trussell J, Polis CB. Population effect of increased access to emergency contraceptive pills. Obstet Gynecol. 2007;109:181-188.